Otolith Labs

Otolith Labs is a chronic care management company, providing a non-invasive and prescription-based wearable device to treat vestibular disorders. The headband device was built based on the company’s proprietary Vestibular System Masking technology, which stimulates the vestibular system (helps regulate the body’s motor functions) through calibrated vibrations for immediate relief.

Furthermore, as at February 2023, the company claimed the device, once approved by the FDA, would be the first of its kind to relieve chronic vertigo. In 2021, the company received Breakthrough Device Designation from the FDA for the treatment of chronic vertigo. American billionaire entrepreneur, Mark Cuban, who had also invested in the company’s seed funding round, had publicly vetted Otolith Labs technology himself being a vestibular patient.

As of October 2022, the device was being tested at three universities in the US, and the company was also enrolling patients for its clinical trials.

Funding and financials

The company received USD 20 million in September 2022 in a Series A funding round led by Morningside Ventures. The new funds were allocated toward clinical trials to obtain the FDA approval and subsequently for the commercialization of its nerve-stimulating wearable device.